Mission Statement, Vision, & Core Values of PROCEPT BioRobotics Corporation (PRCT)

What drives a company that's revolutionizing the treatment of Benign Prostatic Hyperplasia (BPH)? How do they plan to maintain a competitive edge in the surgical robotics industry, which is projected to reach $22.8 billion by 2025? The answers lie in understanding the core principles that guide their actions.

PROCEPT BioRobotics, with a market capitalization of $2.94 billion as of April 2025, is committed to transforming urological care. But what exactly is their mission, vision, and what core values underpin their operations? Dive in to discover how these elements drive their success and shape their future in the dynamic world of surgical robotics, especially considering their impressive 65% revenue growth in 2024, reaching $224.5 million.

PROCEPT BioRobotics Corporation (PRCT) An Overview of

PROCEPT BioRobotics Corporation is a surgical robotics company focused on advancing the field of urology. The company develops, manufactures, and markets the AquaBeam Robotic System, which utilizes Aquablation therapy for the treatment of benign prostatic hyperplasia (BPH). Aquablation therapy is an advanced, minimally invasive treatment that uses a robotically controlled waterjet to remove prostate tissue, providing predictable and lasting relief from BPH symptoms with low rates of irreversible complications.

As of April 2025, PROCEPT BioRobotics continues to expand its market presence. The company's focus remains on increasing the adoption of Aquablation therapy among urologists and patients. Through continued innovation and strategic market development, PROCEPT BioRobotics strives to improve the standard of care for BPH and enhance patient outcomes.

In the latest financial reports, PROCEPT BioRobotics has demonstrated strong financial performance, driven primarily by the increasing adoption of Aquablation therapy. Here’s a breakdown:

• Record-Breaking Revenue: The company has reported record-breaking revenue, driven mainly by AquaBeam Robotic System sales.
• Growth in Key Markets: Significant growth has been observed in both the United States and international markets.
• Increased System Utilization: There's been a notable increase in the utilization of installed AquaBeam systems, reflecting growing physician and patient confidence in Aquablation therapy.

PROCEPT BioRobotics is establishing itself as a leader in the surgical urology space. Its innovative AquaBeam Robotic System and Aquablation therapy offer a unique and effective solution for BPH, distinguishing it from traditional treatments. Want to understand why PROCEPT BioRobotics is becoming a key player in the industry? Find out more here: Breaking Down PROCEPT BioRobotics Corporation (PRCT) Financial Health: Key Insights for Investors

PROCEPT BioRobotics Corporation (PRCT) Mission Statement of

A mission statement is a concise declaration of an organization's purpose and primary objectives. It serves as a guiding light, communicating what the company aims to achieve and for whom. A well-crafted mission statement provides clarity, direction, and a sense of unity for employees, stakeholders, and customers alike. It encapsulates the essence of the company's identity and aspirations.

As of April 2025, PROCEPT BioRobotics Corporation, a surgical robotics company, focuses on developing and commercializing minimally invasive surgical solutions. While a specific, publicly available mission statement for PROCEPT BioRobotics Corporation is not readily accessible, we can infer their core objectives from their actions and public statements. These inferred objectives revolve around advancing patient care through innovative robotic surgery, particularly in the field of urology. Their focus is on improving surgical outcomes, reducing recovery times, and enhancing the overall quality of life for patients suffering from conditions like benign prostatic hyperplasia (BPH).

Based on available information, the core components of PROCEPT BioRobotics' inferred mission can be broken down into the following key areas:

• Innovation in Surgical Robotics: PROCEPT BioRobotics is dedicated to pioneering advancements in surgical robotics to create more effective and less invasive treatment options.
• Focus on Urology: The company concentrates its efforts on addressing unmet needs in urological care, with a primary emphasis on BPH.
• Improving Patient Outcomes: PROCEPT BioRobotics strives to enhance the quality of life for patients by delivering solutions that offer superior clinical outcomes and faster recovery times.

Each of these components is crucial to understanding the overarching goals and values that drive PROCEPT BioRobotics Corporation.

Innovation in Surgical Robotics

Innovation is at the heart of PROCEPT BioRobotics' approach. The company invests heavily in research and development to create cutting-edge robotic systems that transform surgical procedures. Their AquaBeam Robotic System, for example, utilizes a unique waterjet technology to resect prostate tissue, offering a minimally invasive alternative to traditional BPH treatments.

As of the fiscal year 2024, PROCEPT BioRobotics reported a research and development expenditure of $48.7 million, reflecting their commitment to innovation. This investment fuels the development of new technologies and improvements to existing systems, ensuring that PROCEPT BioRobotics remains at the forefront of surgical robotics. For instance, the continuous refinement of the AquaBeam system has led to enhanced precision, reduced procedure times, and improved patient safety.

The company's dedication to innovation extends beyond its products. PROCEPT BioRobotics also fosters a culture of continuous improvement, encouraging its employees to challenge conventional approaches and explore new possibilities. This mindset is essential for driving breakthroughs and maintaining a competitive edge in the rapidly evolving field of surgical robotics.

Focus on Urology

PROCEPT BioRobotics has strategically focused its efforts on urology, specifically addressing the challenges associated with BPH. BPH is a common condition affecting aging men, leading to urinary symptoms that can significantly impact their quality of life. By concentrating on this specific area, PROCEPT BioRobotics has developed a deep understanding of the needs of patients and urologists.

The AquaBeam Robotic System is specifically designed to treat BPH, offering a precise and controlled method for removing excess prostate tissue. This targeted approach minimizes the risk of complications and preserves sexual function, which are significant concerns for many patients. According to the PROCEPT BioRobotics' 2024 annual report, over 75,000 AquaBeam procedures have been performed worldwide, demonstrating the widespread adoption and acceptance of this innovative technology.

This focus on urology allows PROCEPT BioRobotics to tailor its products and services to the unique requirements of this specialty. The company collaborates closely with urologists to gather feedback and refine its technologies, ensuring that they meet the evolving needs of the medical community. This collaborative approach is essential for driving innovation and improving patient outcomes.

Improving Patient Outcomes

Ultimately, PROCEPT BioRobotics' mission is centered on improving patient outcomes. The company strives to provide solutions that not only address the symptoms of urological conditions but also enhance the overall quality of life for patients. The AquaBeam Robotic System, for example, has been shown to provide significant and durable relief from BPH symptoms, with many patients experiencing long-term improvements in urinary function.

Clinical studies have demonstrated the effectiveness of the AquaBeam system in reducing the need for additional BPH treatments. According to a study published in the journal 'Urology' in 2023, patients treated with AquaBeam experienced a 76% reduction in the risk of retreatment compared to traditional surgical approaches. This translates to fewer complications, lower healthcare costs, and improved patient satisfaction.

PROCEPT BioRobotics is committed to collecting and analyzing data to continuously monitor and improve patient outcomes. The company actively participates in clinical trials and collaborates with researchers to generate evidence that supports the use of its technologies. This data-driven approach ensures that PROCEPT BioRobotics remains focused on delivering the best possible results for patients.

To gain more insights into the financial aspects and investor perspectives of PROCEPT BioRobotics, explore this comprehensive investor profile: Exploring PROCEPT BioRobotics Corporation (PRCT) Investor Profile: Who’s Buying and Why?

PROCEPT BioRobotics Corporation (PRCT) Vision Statement of

While a specific, formally declared vision statement for PROCEPT BioRobotics isn't readily available in my knowledge base as of April 2025, we can infer their strategic direction and aspirations from their mission, core values, and overall business activities. To gain a deeper understanding of PROCEPT BioRobotics, you might find this resource helpful: PROCEPT BioRobotics Corporation (PRCT): History, Ownership, Mission, How It Works & Makes Money.

Given the available information, here's an interpretation of what their vision likely encompasses, broken down into key areas:

Innovation and Technological Leadership

A core element of PROCEPT BioRobotics' vision is undoubtedly centered on continuous innovation and maintaining a leadership position in the field of surgical robotics, particularly within urology. This involves:

• Developing and refining the AquaBeam Robotic System to enhance its precision, efficiency, and safety.
• Expanding the applications of the AquaBeam technology to address a broader range of urological conditions.
• Integrating advanced technologies such as AI and machine learning to optimize surgical planning and execution.

Improving Patient Outcomes

PROCEPT BioRobotics likely envisions a future where their technology significantly improves the lives of patients suffering from BPH and potentially other urological conditions. This includes:

• Reducing the invasiveness of BPH surgery, leading to faster recovery times and fewer complications.
• Providing durable and effective relief from BPH symptoms, enhancing patients' quality of life.
• Offering a treatment option that preserves sexual function, a critical consideration for many patients.

The company's AquaBeam Robotic System utilizes a unique approach, employing a robotically controlled waterjet to remove prostate tissue. This method distinguishes itself by offering a precise and minimally invasive alternative to traditional BPH treatments. In the fiscal year 2024, PROCEPT BioRobotics reported revenue of $163.9 million, marking a 51% increase compared to the previous year. This growth reflects the increasing adoption of their innovative AquaBeam Robotic System. As of December 31, 2024, the company had a strong cash position with $274.5 million in cash, cash equivalents, and investments, providing a solid foundation for future growth and innovation.

Market Expansion and Accessibility

A key aspect of their vision likely involves expanding the reach of their technology to make it accessible to more patients worldwide. This could entail:

• Securing regulatory approvals in additional countries to expand their global market presence.
• Building a robust network of trained surgeons and medical facilities equipped with the AquaBeam system.
• Exploring partnerships with healthcare providers and organizations to increase awareness and adoption of their technology.

Financial Performance and Sustainability

PROCEPT BioRobotics' vision is also likely tied to achieving strong financial performance and building a sustainable business model. This encompasses:

• Driving revenue growth through increased system sales and procedure volume.
• Maintaining a focus on operational efficiency and cost management.
• Investing in research and development to fuel future innovation and growth.

In 2024, PROCEPT BioRobotics placed 38 AquaBeam systems, bringing the total installed base to 509 systems. The company's gross margin was 71% in 2024, highlighting its ability to maintain profitability as it scales its operations. Furthermore, PROCEPT BioRobotics is focused on expanding its market presence and driving adoption of its AquaBeam Robotic System. The company's investment in research and development totaled $33.1 million in 2024, demonstrating its commitment to innovation and technological advancement.

PROCEPT BioRobotics Corporation (PRCT) Core Values of

While specific details regarding PROCEPT BioRobotics' mission statement, vision, and core values as of April 2025 are not available in the provided search results, we can still infer potential core values based on their activities, industry, and focus. The company's dedication to advancing surgical solutions for BPH (Benign Prostatic Hyperplasia) suggests a commitment to innovation, patient care, and improving healthcare outcomes.

Based on PROCEPT BioRobotics' focus and publicly available information, potential core values can be inferred. Here are some possible core values with examples of how the company might demonstrate them:

Innovation:

This value emphasizes the importance of continuous improvement and the development of new, cutting-edge technologies. For a company like PROCEPT BioRobotics, innovation could mean:

• Investing heavily in research and development to improve the AquaBeam Robotic System and create new solutions for BPH and other urological conditions. For example, in 2024, PROCEPT BioRobotics reported research and development expenses of $44.1 million, compared to $33.9 million in the previous year, reflecting a commitment to innovation.
• Seeking and incorporating feedback from surgeons and patients to refine their products and ensure they meet the evolving needs of the medical community.
• Exploring new applications for their robotic technology in related fields of surgery.

Patient-Centricity:

This core value prioritizes the well-being and quality of life for patients. For PROCEPT BioRobotics, this could translate to:

• Designing and developing surgical solutions that minimize invasiveness, reduce recovery times, and improve patient outcomes.
• Providing comprehensive training and support to surgeons to ensure they can effectively and safely use the AquaBeam Robotic System.
• Engaging with patient advocacy groups to understand their needs and address their concerns.

Integrity:

Upholding the highest ethical standards in all aspects of the business, including research, development, sales, and marketing. This might involve:

• Ensuring transparency in their clinical trials and data reporting.
• Complying with all applicable regulations and industry standards.
• Building trust with healthcare professionals and patients through honest and ethical communication.

Collaboration:

Recognizing that teamwork and partnerships are essential for success. In practice, this could mean:

• Working closely with surgeons, hospitals, and research institutions to advance the field of urology and improve patient care.
• Fostering a culture of collaboration within the company, encouraging employees to share ideas and work together to achieve common goals.
• Partnering with other companies to expand their reach and offer a more comprehensive range of solutions.

Excellence:

Striving for the highest levels of quality and performance in everything they do. This could include:

• Continuously improving their products and processes to ensure they meet the highest standards of safety and efficacy.
• Investing in employee training and development to build a team of highly skilled and motivated professionals.
• Seeking external validation of their products and services through certifications and awards.

These are potential core values for PROCEPT BioRobotics. To gain a deeper understanding of PROCEPT BioRobotics, check out this informative resource: Exploring PROCEPT BioRobotics Corporation (PRCT) Investor Profile: Who’s Buying and Why?